• Important agreement with significant sales and revenue potential
• Development of a new pump to deliver a leading rare disease drug, using proven pump technology from Gerresheimer
• Sensile pump by Gerresheimer designed to improve quality of life with ease of use
• High existing patient demand for pump systems to deliver the product expected to lead to prompt realization and implementation on the market
• Long-term collaboration envisaged: a major American biotech relies on integral solution and innovation strength of Gerresheimer

Gerresheimer has entered an important agreement involving its Advanced Technologies division. An established US biotech company will rely on Gerresheimer’s innovative strength and engineering expertise for the development of a new pump to deliver a leading drug for the treatment of rare diseases via continuous parenteral administration.

“This agreement is another important milestone on our way to becoming a solution provider for leading and innovative medical devices.” said Dietmar Siemssen, CEO of Gerresheimer AG. “Our patented pump technology has already proven itself in use for Parkinson’s therapy and in future we expect it will also help to improve the quality of life of people with rare diseases. Our broad portfolio for the pharma and biotech industry makes it possible to develop the best solution together with our customers and implement it with a perfect fit.”

The pump for the continuous parenteral administration of the liquid drug will be specially adapted by Gerresheimer to the needs of patients with this rare disease. The sales and revenue model is divided into two phases. First, the American biotech will fund the development of the pump. After the market launch, Gerresheimer will sell the pump to the biotech and receive both a transfer price and royalty. The project is already making a positive contribution to earnings development from the start – clear evidence of the successful implementation of the growth strategy.

The exclusive agreement between Gerresheimer and the American biotech addresses the regions USA and Canada, with a right of first refusal granted to the partner to cover additional